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Background: Angiogenesis plays an important role in the development of rheumatoid arthritis (RA), which in-
creases the supply of nutrients, cytokines, and inﬂammatory cells to the synovial membrane. Genistein (GEN), a
soy-derived isoﬂavone, has been validated that can effectively inhibit the angiogenesis of several tumours. We
thus carried out a study in vitro to investigate the effect of GEN in vascular endothelial growth factor (VEGF)
expression and angiogenesis induced by the inﬂammatory environment of RA.
Methods: MH7A cells were used to verify whether GEN can inhibit the expression of VEGF in MH7A cells under
inﬂammatory conditions and demonstrate the mechanism. EA.hy926 cells were used to verify whether GEN can
inhibit the migration and tube formation of vascular endothelial cells in inﬂammatory environment.
Results: GEN dose-dependently inhibited the expression and secretion of interleukin (IL)-6 and VEGF, as well as
the nucleus translocation of Signal transducer and activator of transcription 3 (STAT3) in MH7A. Furthermore,
GEN inhibited IL-6–induced vascular endothelial cell migration and tube formation in vitro.
Conclusion: GEN inhibits IL-6–induced VEGF expression and angiogenesis partially through the Janus kinase 2
(JAK2)/STAT3 pathway in RA, which has provided a novel insight into the antiangiogenic activity of GEN in RA.
The translational potential of this article: Our study provides scientiﬁc guidance for the clinical translational research
of GEN in the RA treatment.Medicine Research and Development, Shen Zhen Institute of Advanced Technology, Chinese Academy of Science,
055,China.
y of Orthopaedic Implant, Department of Orthopaedics, Shanghai Ninth People's Hospital, Shanghai Jiao Tong
Shanghai 200011, China.
, peng.zhang@siat.ac.cn (P. Zhang).
and should be considered co-ﬁrst authors
rm 22 July 2019; Accepted 28 July 2019
ier (Singapore) Pte Ltd on behalf of Chinese Speaking Orthopaedic Society. This is an open access article under the
enistein inhibits angiogenesis developed during rheumatoid arthritis through the IL-6/JAK2/STAT3/
edic Translation, https://doi.org/10.1016/j.jot.2019.07.007
W.-X. Cheng et al. Journal of Orthopaedic Translation xxx (xxxx) xxxIntroduction
Rheumatoid arthritis (RA) is an autoimmune disease that triggers the
synovial membrane inﬂammation, cartilage damage, and bone erosion
and primarily targets the small joints of the hands, with 1% prevalence
worldwide [1,2]. Uncontrolled active RA leads to disability, decreased
quality of life, and increased comorbidity [3]. Thus, the discovery and
development of a safe and effective drug that is able to inhibit RA remain
an important goal. With the development of RA, pannus will gradually
form in the affected joints, which progressively destroys and erodes the
cartilage, resulting in joint deformity and loss of function [4]. Angio-
genesis is a prominent feature of the formation of pannus; the prolifer-
ation of blood vessels can not only supply more nutrition for the growth
of synovial membrane but also provide a diffusion channel for cytokines
and inﬂammatory cells [5]. Because angiogenesis is an important chan-
nel for leucocyte inﬁltration into the synovial membrane in the devel-
opment and progression of RA, blocking angiogenesis may inhibit
synovial inﬂammation and the formation of pannus and thus inhibit the
occurrence and development of RA [6], for which angiogenesis has
gradually become a promising target in the treatment of RA.
Genistein (40, 57-trihydroxyisoﬂavone, GEN), a natural isoﬂavone
compound present in leguminous plants, has aroused considerable
concern because of its potential effects on cardiovascular disease, oste-
oporosis, and hormone-related cancers [7]. It has been shown that GEN
can effectively inhibit the proliferation of endothelial cell and angio-
genesis and can inhibit different types of cancer by inhibiting metastasis
and angiogenesis, altering cell apoptosis and cell cycle, and so on [8,9].
Buchler et al. [10] has proved that GEN reduces the expression of
angiogenesis factors in tumour. There is some commonality in the pa-
thology of RA and tumours; both the diseases involve the abnormal
proliferation of cells and ﬁnally lead to hypoxia and angiogenesis. More
and more studies related to the role of GEN in the treatment of RA were
carried out. Our previous research results also showed that GEN exerted
antiinﬂammatory and antiangiogenesis properties in a collagen-induced
RA (CIA) model and signiﬁcantly reduced the expression of some
inﬂammation factors, such as tumour necrosis factor (TNF)-α and inter-
leukin (IL)-6, as well as vascular endothelial growth factor (VEGF) [11,
12]. Besides for inducing inﬂammatory reaction, IL-6 may also be an
important regulatory molecule in both physiologic and pathologic
angiogenesis [13]. Zhao et al. [14] and Zhu et al. [15] have suggested
that IL-6 can increase the expression of VEGF through the Janus kin-
ase/Signal transducer and activator of transcription 3 (JAK/STAT3)
signalling pathway. Several studies have showed that abnormal activa-
tion of STAT3 can signiﬁcantly promote the expression of VEGF and
angiogenesis, which can be reversed when STAT3 activation is sup-
pressed [16,17]. Therefore, the inhibition of IL-6 and VEGF by GEN in RA
indicates the great potential of GEN in antiangiogenesis, and there is a
possibility that GEN inhibits the expression of VEGF in RA via
IL-6/JAK/STAT3/VEGF pathway.
In the present study, we examined whether and how the GEN inhibits
angiogenesis in RA. We found that GEN can inhibit the migration and
tube formation of human vascular endothelial cells under the inﬂam-
matory environment and regulate the expression and secretion of VEGF
in RA via the IL-6/JAK2/STAT3/VEGF pathway. Our works further
demonstrate the molecular mechanism underlying the antiangiogenic
activity of GEN and its great potential in the treatment of RA.
Materials and methods
Cell culture
MH7A cells were purchased from the Riken Cell Bank (Tsukuba,
Japan). The cellswere cultured inRoswell ParkMemorial Institute (RPMI)
1640medium (Hyclone, Thermo Fisher Scientiﬁc,Wilmington, DE, USA),
with 10% foetal bovine serum (Gibco, Thermo Fisher Scientiﬁc), and 1%
penicillin/streptomycin (Sigma–Aldrich, MO, USA). EA.hy926 cells were2cultured in DulbeccoModiﬁed EagleMedium (DMEM)mediumwith high
glucose, supplemented with 10% foetal bovine serum (Gibco, Thermo
Fisher Scientiﬁc) and 1% penicillin/streptomycin (Sigma–Aldrich). All
cell lines were cultured in an incubator with the constant temperature of
37C, constant humidity, and 5% of CO2.
In vitro cytotoxicity tests (Cell counting kit - 8 (CCK-8) assay)
MH7A cells and EA.hy926 cells were seeded into 96-well culture
plates (5000 cells/well) for 24 h and then supplemented with different
concentrations of GEN (Sigma–Aldrich) for 24 h or 48 h. Subsequently,
CCK-8 (Dojindo, Japan) was added into each well, ensuring the volume
of CCK-8 is 10% of the volume of medium. Then, the cells were incubated
at 37 C for 2 h, and the absorbance was detected at 450 nm using a
microplate reader (PerkinElmer, Waltham, MA). The cytotoxicity was
expressed as the relative viability (%), with no GEN in the culture media
representing 100%.
RNA extraction, reverse transcription, and real time quantitative
polymerase chain reaction (qPCR)
MH7A cells were seeded in 6-well plates at 1 106 cells/well for 24 h.
The cells were pretreated with AG490/GEN (Sigma–Aldrich) at indicated
concentrations for 2 h and then stimulated with TNF-α (10 ng/mL; R&D
Systems, Minneapolis, MN, USA) or IL-6 (50 ng/mL; Sigma–Aldrich) for
24 h. According to the manufacturer's instructions, total RNA of the cells
was extracted using the commercial total RNA miniprep kit (Corning,
Inc., Axygen, NY, USA). Then, each RNA sample was reverse transcribed
using a complementary DNA (cDNA) synthesis kit according to the
manufacturer's protocol. qPCR analysis was performed using SYBR Green
PCR Premix Ex Taq II reagents (Takara Bio Inc., Kusatsu, Japan) on a
Light Cycler 480 II real-time system (Roche, Mannheim, Germany).
Glyceraldehyde 3-phosphate dehydrogenase (GAPDH), a house-keeping
gene, was used for normalising the result of qPCR.
Enzyme-linked immunosorbent assay
MH7A cells were seeded in 6-well plates at 1 106 cells/well for 24 h.
The cells were pretreated with AG490/GEN (Sigma–Aldrich) at indicated
concentrations for 2 h and then stimulated with TNF-α (10 ng/mL; R&D
Systems) or IL-6 (50 ng/mL; Sigma–Aldrich) for 24 h. The concentrations
of cytokines in the culture medium were detected using corresponding
commercial enzyme-linked immunosorbent assay kits (R&D Systems). A
standard curve was constructed for each assay according to the manu-
facturer's instructions, and the concentrations of cytokines were calcu-
lated on the basis of the standard curve.
Western blotting
MH7A cells were seeded in 6-well plates at 1 106 cells/well for 24 h.
The cells were pretreated with AG490/GEN (Sigma–Aldrich) at indicated
concentrations for 2 h and then stimulated with IL-6 (50 ng/mL; Sig-
ma–Aldrich) for 1 h to determine the p-STAT3 protein level and for 24 h
to determine the STAT3 protein level. The cells were lysed by lysis buffer
(Radio-Immunoprecipitation Assay (RIPA) Thermo Fisher Scientiﬁc) in a
cold environment and then the lysed cells and lysis buffer were collected
in a tube and centrifuged at 12,000 rpm for 25 min to remove the cell
fragments. The protein concentration was measured using the bicin-
choninic acid (BCA) kit (Thermo Fisher Scientiﬁc), and then the protein
was heated with sodium dodecyl sulphate–polyacrylamide gel electro-
phoreses sample-loading buffer (Beyotime Institute of Biotechnology,
Haimen, China) to denature the protein. Fifty micrograms of the dena-
tured protein from each sample was separated by 12% sodium dodecyl
sulphate–polyacrylamide gel electrophoreses under a constant voltage of
110 V. Then, the separated protein was transferred to a polyvinylidene
ﬂuoride membrane (Millipore Co, Bedford, MA) under a constant current
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target protein was blocked with 5% skim milk in phosphate buffered
solution with Tween-20 (PBST) at room temperature for 1 h and then
incubated with speciﬁc antibody solution overnight at 4C. The poly-
vinylidene ﬂuoride membrane was washed with PBST to remove the
redundant antibodies, and then the membrane was incubated with the
corresponding second antibody at room temperature for 1h. An enhanced
Electrochemiluminescence (ECL) detection system was used to detect the
antibody binding, and the results were quantiﬁed using Image-pro plus
7.0 (Image-Pro Plus Inc.,Maryland, USA). The antibodies STAT3 and
phospho-STAT3 (tyr-705) were purchased from Cell Signalling Tech-
nology (Beverly, MA, USA), and the antibody for GAPDH was purchased
from Abcam (Cambridge, UK).
Transwell assay
EA.hy926 cells were seeded in the upper chamber of a 24-well
transwell plate at 2  104 cells/well (pore size ¼ 8 μm; Corning, Inc.
Corning, NY, USA). Then, 600 μL of mediumwith or without IL-6 (50 ng/
mL; Sigma–Aldrich) and GEN (Sigma–Aldrich) at an indicated concen-
tration was separately added to the lower chamber. After incubation at
37C for 3 h, the upper chamber was taken out and washed with Phos-
phate buffered solution (PBS). The cells on the upper surface of the ﬁlter
membranes were wiped off gently using a cotton swab, and the cells that
migrated to the lower surface were ﬁxed with 4% paraformaldehyde for
30 min and stained with 0.5% crystal violet for 10 min. The migrated
cells on the lower surface of the ﬁlter membranes were observed using an
inverted microscope; 10 ﬁelds from each group were randomly selected
for taking photographs using a microscope (CKX41, Olympus Inc.,Shin-
juku, Tokyo, Japan) equipped with a 20  objective lens and a digital
camera (Olympus Inc., Shinjuku, Tokyo, Japan). The migrated cells in
each ﬁeld were counted using Image-Pro Plus software.
Wound healing assay
EA.hy926 cells were seeded in a 6-cm dish at 5  105 cells/well and
incubated at 37C for 24 h. After monolayers of EA.hy926 were formed in
the dish, the monolayers were scratch using a sterile 1000-μL tip to create
a wound and it was marked. Then, the dishes were washed with PBS to
remove the cells that have been scraped off, serum-free medium with or
without (50 ng/mL; Sigma–Aldrich) and GEN (Sigma–Aldrich) was
added to the dishes, and they were incubated at 37C for 24 h. The
migrated cells on the wounded area were observed using an inverted
microscope at 0 h and 24 h after wounding, and 6 marked ﬁelds were
selected for each group for taking photographs using a microscope
(Olympus) equipped with a 20  objective lens and a digital camera
(Olympus). Width of the wound was determined using Image-Pro Plus7.0
(Image-Pro Plus Inc., Maryland, USA), and the speed of cell migration
was expressed as the percentage of the originally wounded width.
Tube formation assays
EA.hy926 cells were seeded in a 24-well plate precoated with 500 μL
of Matrigel (Corning, Inc.) per well at 3  104 cells/well. The cells were
treated with or without IL-6 (50 ng/mL; Sigma–Aldrich) and GEN (Sig-
ma–Aldrich) for 6 h at 37C. The tube formation of EA.hy926 in the
Matrigel was observed using an inverted microscope, and 8 ﬁelds were
randomly selected for taking photographs using a microscope (Olympus)
equipped with a 20 objective lens and a digital camera (Olympus). The
length of the master segments and the number of branching points were
analysed using (Image J, NIH, US).
Coculture of MH7A and EA.hy926
The effect of inﬂammatory environment on EA.hy926 migration was
assessed by coculture withMH7A in transwells. In brief, MH7A cells were3seeded in a 24-well plate at 1  105 cells/well for 24 h and then stim-
ulated with or without TNF-α (10 ng/mL) for 24 h in the presence of
AG490 or GEN at indicated concentrations. Then, EA.hy926 cells were
seeded in the upper chamber of a 24-well transwell plate (pore size ¼ 8
μm; Corning, Inc.) at 2  104 cells/well. After incubation at 37C for 3 h,
the upper chamber was taken out and washed with PBS. The cells on the
upper surface of the ﬁlter membranes were wiped off gently using a
cotton swab, and the cells that migrated to the lower surface were ﬁxed
with 4% paraformaldehyde for 30 min and stained with 0.5% crystal
violet for 10 min. The migrated cells on the lower surface of the ﬁlter
membranes were observed using an inverted microscope, 10 ﬁelds were
randomly selected from each group for taking photographs using a mi-
croscope (Olympus) equipped with a 20  objective lens and a digital
camera (Olympus). The migrated cells in each ﬁeld were counted using
Image-Pro Plus software.
Confocal laser scanning ﬂuorescence microscopy
MH7A cells were cultured on a glass coverslip at about 5 103 cells for
24 h, the coverslip was gently washedwith PBS to rip off themedium, and
the cells that were stuck on the coverslip were ﬁxed with 4% para-
formaldehyde for 20 min. The coverslip was washed with PBS and incu-
batedwith p-STAT3 antibody (diluted 1:100) at room temperature for 1 h.
It was washed again and incubated with ﬂuoresceine isothiocyanate
(FITC) conjugated second antibody (Santa Cruz Biotechnology, Santa
Cruz, CA, USA) at room temperature for 1 h. The coverslip was washed
with PBS, and the nucleiwas stainedwithﬂuorescent dye 4-, 6-diamidino-
2-phenylindoledihydrochloride (Sigma–Aldrich) at room temperature for
3 min, avoiding light. The stained cells were observed using a confocal
laser scanning ﬂuorescence microscope (TCSSP5-II; Leica Inc.,Wetzlar,
Hesse, Germany) to detect the distribution of p-STAT3 in MH7A cells.
Statistical analysis
All the data were simply analysed by Excel Inc., Redmond, Wash-
ington State, US and further analysed using SPSS 17.0 software (SPSS
Inc., Chicago, IL, USA). One-way analysis of variance followed by Den-
nett's t test was used to understand whether the differences between the
groups are statistically different. When p < 0.05, the difference between
the groups was considered signiﬁcant. The ﬁnal data were presented as
mean  standard deviation (SD), and the histogram was created using
GraphPad Prism 5.0 (GraphPad Software Inc., San Diego, CA, USA).
Results
Cytotoxicity of GEN on MH7A and EA.hy926 cells
To avoid the cytotoxic effect of GEN on the cells, the effect of different
concentrations of GEN on cell viability was determined by CCK-8, the
maximum safe concentration of GEN was ascertained, and the effect of
the cytotoxicity of GEN on the experimental results was eliminated. As
shown in Fig. 1, when the cells were incubated with GEN for 24h, there
are no cytotoxic effects of GEN on EA.hy926 cells, even at the highest
concentration (60 μmol/L) and there was no cytotoxic effect of GEN on
MH7A cells when the concentration was not higher than 25 μmol/L.
When the cells were incubated with GEN for 48 hh, there was no cyto-
toxic effect of GEN on both EA.hy926 cells and MH7A cells when the
concentration was not higher than 25 μmol/L, as a result of which we
consider the concentration of 25 μmol/L to be the highest concentration
within the safe range, and the concentration of GEN in the following
experiment will not be higher than 25 μmol/L.
GEN inhibits IL-6 and VEGF induction by TNF-α in MH7A cells
There is ample evidence that excessive inﬂammatory cytokines, such
as TNF-α and IL-1β, play an important role in the pathogenesis of RA. We
Figure 1. Cytotoxicity of GEN on MH7A and EA.hy926 cells. Cells were treated with different concentrations of GEN for 24 and 48 h, and their viability was
determined using Cell counting kit-8 (CCK-8) assay. (A) Cytotoxicity of GEN on EA.hy926 cells; (B) cytotoxicity of GEN on MH7A cells (means  SD, n ¼ 6, *P < 0.05,
**P < 0.01). GEN ¼ genistein; SD ¼ standard deviation.
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production [11]. As there are several studies that show IL-6 can
directly induce vessel sprouting, as well as the proliferation and migra-
tion of endothelial cells, there might exist some close relation between
IL-6 and VEGF [18,19]. We further assessed the effect of GEN on IL-6 and
VEGF expression induced by TNF-α in RA. MH7A cells were pretreated
with GEN at different concentrations for 2 h and then stimulated with
TNF-α (10 ng/mL) for 24 h. The mRNA expression of IL-6 and VEGF in
MH7A cell was analysed by qPCR, and the protein level of IL-6 and VEGFFigure 2. Protein and mRNA expression of cytokines in MH7A cells. MH7A cells were
TNF-α (10 ng/mL) for 24 h; the protein content of IL-6 and VEGF in the MH7A cell cul
in MH7A cells were analysed by qPCR. (A) Protein content of IL-6 in the MH7A cel
pernatant; (C) mRNA expression of IL-6 in MH7A cells; (D) mRNA expression of VEG
linked immunosorbent assay; GEN ¼ genistein; IL-6 ¼ interleukin-6; SD ¼ standa
growth factor.
4in the MH7A cell culture supernatant was measured by enzyme-linked
immunosorbent assay. As shown in Fig. 2, there was a basal expression
of IL-6 and VEGF in MH7A cells. After stimulation with TNF-α, the mRNA
expression of IL-6 and VEGF was apparently upregulated and the protein
expression of IL-6 and VEGF in the culture supernatant was also signiﬁ-
cantly increased. However, pretreated MH7A cells with GEN can signif-
icantly reduce the expression and release of IL-6 and VEGF and present a
dose-dependent property, which indicates that GEN can effectively
inhibit the production of IL-6 and VEGF induced by TNF-α in RA.pretreated with GEN at different concentrations for 2 h and then stimulated with
ture supernatant was measured by ELISA, and the mRNA levels of IL-6 and VEGF
l culture supernatant; (B) protein content of VEGF in the MH7A cell culture su-
F in MH7A cells (means  SD, n ¼ 6, *P < 0.05, **P < 0.01). ELISA ¼ enzyme-
rd deviation; TNF-α ¼ tumour necrosis factor-α; VEGF ¼ vascular endothelial
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It is reported that anti–IL-6 antibody therapy can effectively alleviate
arthritis and that anti–IL-6R antibody therapy can reduce the level of
VEGF in serum of patients with RA, suggesting that IL-6 plays an
important role in promoting angiogenesis and has an important inﬂuenceFigure 3. Migration and tube formation of EA.hy926 cells. (A) Migration of EA.hy92
tube formation of EA.hy926 cells on Matrigel; (D) the number of EA.hy926 cells on m
branching points of the tube in a ﬁeld; (G) master segment length of the tube in a
interleukin-6; SD ¼ standard deviation.
5on the pathogenesis of RA [20,21]. Therefore, we explore the effect of
IL-6 on the vascular process of EA.hy926 and verify whether GEN can
inhibit migration of EA.hy926 in the environment of inﬂammation and
angiogenesis simulated by IL-6. Transwell assay and wound healing assay
were used for this purpose. In the transwell assay, the conditional media
stimulated with IL-6 promoted the migration of EA.hy926 and that6 cells on membranes of the transwell; (B) wound healing of EA.hy926 cells; (C)
embranes of the transwell in each group; (E) % of wound healing in 24 hh; (F)
ﬁled (means  SD, n ¼ 8, *P < 0.05, **P < 0.01). GEN ¼ genistein; IL-6 ¼
W.-X. Cheng et al. Journal of Orthopaedic Translation xxx (xxxx) xxxtreated with GEN signiﬁcantly reduced the number of migrated cells after
IL-6 stimulation (Fig. 3 A). In the wound healing assay, the cells pre-
sented a similar trend with the transwell assay. When stimulated with
IL-6, the speed of wound healing was increased signiﬁcantly and cells
when treated with GEN inhibited the healing ability of EA.hy926 at 24 h
(Fig. 3 B).GEN inhibits tube formation of EA.hy926
To further evaluate the effect of GEN on angiogenesis, we assess the
tube formation of EA.hy926 in vitro. The results show that EA.hy926
cells have good ability of forming tube under normal conditions and can
form large reticular structures on the Matrigel. After treatment with IL-6,
the capacity of tube formation is increased, although there is noFigure 4. The number of EA.hy926 cells on membranes of the transwell when cocult
when the medium in the lower chamber contains TNF-α; (C) EA.hy926 cells on memb
membranes of the transwell when MH7A cells were treated with TNF-α; (E) EA.hy926
and AG490 (25 ng/ml); (F) EA.hy926 cells on membranes of the transwell when M
EA.hy926 cells on membranes of the transwell in each group (means  SD, n ¼ 10, *P
necrosis factor-α.
6signiﬁcant difference in statistics; both the master segment length and
the amount of branching points are upregulated. After treating with GEN,
the tube forming ability of EA.hy926 cells is greatly reduced, and there
are a large number of cells scattered in the ﬁeld of vision (Fig. 3C). As
shown in Fig. 3 F and G, analysing the images using Image J, the results
show that GEN can effectively inhibit the tube formation of EA.hy926
and has a signiﬁcant dose effect.Coculture of MH7A and EA.hy926
Our experiments have shown that GEN can effectively inhibit the
migration and angiogenesis of vascular endothelial cells in the inﬂam-
mation and angiogenesis environment simulated by IL-6. To better
simulate the inﬂammatory environment in patients with RA, weured with MH7A. (A) Control; (B) EA.hy926 cells on membranes of the transwell
ranes of the transwell when cocultured with MH7A cells; (D) EA.hy926 cells on
cells on membranes of the transwell when MH7A cells were treated with TNF-α
H7A cells were treated with TNF-α and GEN (25 μmol/L); (G) The number of
< 0.05, **P < 0.01). GEN ¼ genistein; SD ¼ standard deviation; TNF-α ¼ tumour
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further explore the effect of GEN on angiogenesis in RA. As shown in
Fig. 4, when EA.hy926 cells are cocultured with MH7A or treated with
TNF-α, the migration of EA.hy926 was promoted, which indicates that
MH7A will secrete some promoting factors for migration of the vascular
endothelial cells. We further treat MH7A cells with TNF-α to simulate the
inﬂammation environment in RA and then coculture with EA.hy926,
which signiﬁcantly promoted the migration of EA.hy926 cells. However,
MH7A cells treated with AG490, the inhibitor of JAK/STAT signalling
pathway, can effectively block this promotion, and MH7A cells treated
with GEN show a similar effect with AG490 on the migration of
EA.hy926, which indicates that GENmight inhibit the angiogenesis in RA
by JAK/STAT pathway.
GEN inhibits IL-6–induced VEGF expression via JAK/STAT signalling
pathway
To elucidate weather GEN inhibited VEGF expression in RA
through JAK/STAT pathway, we used JAK/STAT signalling pathway
inhibitor AG490 as a positive control. We found that the expression of
VEGF mRNA and secretion of VEGF protein in MH7A cells was
signiﬁcantly increased when stimulated with IL-6 (50 ng/mL) for 24 h.
There is a 23.4% increase in the expression of VEGF mRNA and a
41.4% increase in the protein level of VEGF. When the cells were
pretreated with GEN, the expression of VEGF mRNA and the protein
level presented a dose-dependent reduction. What is more, in the cells
pretreated with 25 ng/ml of AG490, the expression of VEGF mRNA and
the protein level in MH7A cells were also reduced signiﬁcantly (Fig. 5A
and B). These results indicated that GEN may inhibit the expression of
VEGF in MH7A cells via JAK/STAT signalling pathway, for which we
further measured the mRNA expression of JAK2 and STAT3 in MH7A
cells. Results showed that IL-6 (50 ng/mL) increased the expression of
JAK2 and STAT3 and GEN can effectively reverse this situation
(Fig. 5C and D).
GEN inhibits the activation of STAT3
To assess the effect of GEN on the activation of STAT3 in RA, we
detected the levels of phospho-STAT3 in MH7A cells by Western blotting.
As shown in Fig. 5 E, STAT3 was constitutively activated in MH7A cells,
and when treated with GEN or AG490, the activation of STAT3 was
effectively inhibited without affecting the expression of total STAT3,
which directly proved that GEN can effectively inhibit the activation of
STAT3 and thus block the JAK/STAT pathway.
GEN inhibits STAT3 nuclear translocation
To assess the effect of GEN on the nuclear translocation of STAT3, we
detect the content of p-STAT3 in the nucleus of MH7A. As shown in
Fig. 5, under normal conditions, STAT3 is continuously activated and
distributed throughout the cell. When the cells were stimulated by IL-6
(50 ng/mL) for 1 h, the activated STAT3 abnormally gathers in the nu-
cleus of MH7A. However, if the cells were pretreated by GEN before
stimulated by IL-6, the abnormal nuclear translocation of p-STAT3will be
suppressed (Fig. 5F and G). This result strongly proved that GEN can
inhibit the IL-6–induced nuclear translocation of p-STAT3 and may
therefore reduce IL-6–induced expression of VEGF in MH7A.
Discussion
GEN, an isoﬂavone abundant in soybeans, has gained signiﬁcant
attention because of its potential role in preventing and treating many
disorders. It has been reported that GEN has signiﬁcant effects on anti-
inﬂammation and immunoregulation [11,22]. Studies have shown that
GEN can relieve inﬂammation and inhibit angiogenesis in the CIA animal7model; meanwhile, it can also lower the expression of IL-6 and VEGF [12,
23,24]. In addition, GEN has also been demonstrated to inhibit the
expression of VEGF and angiogenesis in tumours [25,26]. In the course of
angiogenesis, both the overexpression of VEGF and overactivation of
STAT3 play a role that cannot be neglected [17,27–29], and some
research groups have found that IL-6 can increase the expression of VEGF
and angiogenesis by activating STAT3 in tumours [14,15,30]. Upregu-
lation of various proinﬂammatory and angiogenic mediators orchestrates
the typical pathological synovial alterations in RA. Many factors, such as
hypoxia-inducible factor, inﬂammatory factors, and so on, can increase
the VEGF expression [31]. However, it remains to be clariﬁed whether
GEN can inhibit the expression of VEGF and angiogenesis in RA by STAT3
pathway. In this study, we have indicated that GEN inhibited the
expression of VEGF and angiogenesis in RA by partially suppressing the
activation and nucleus translocation of STAT3, based on our preliminary
ﬁndings. To explore the effect of GEN on the expression of IL-6 and VEGF
induced by the inﬂammation environment in RA, we detected the
expression of these two factors in MH7A cells treated with TNF-α. As
shown in Figs. 2 and 3, a signiﬁcant increase on the mRNA level and
protein level of IL-6 and VEGF was observed when MH7A cells were
stimulated by TNF-α (10 ng/mL). Interestingly, when the cells are pre-
treated with GEN before stimulated by TNF-α, this situation be reversed
effectively; both the mRNA levels and protein levels of IL-6 and VEGF
decreased in a dose-dependent manner. Such a result demonstrates that
GEN can inhibit the expression of IL-6 and VEGF induced by inﬂamma-
tion in RA.
Angiogenesis plays an important role in RA, for which we further
evaluated the effect of GEN on the migration and tube formation of
EA.hy926 cells. As shown in Figs. 4 and 5, IL-6 promoted the migration of
EA.hy926 cells, which can be abrogated by GEN. In addition, GEN can
also suppress the tube formation of EA.hy926. These ﬁndings indicate
that GEN possesses a good property of antiangiogenesis, even under the
stimulation of IL-6, and provides a strong proof that GEN may inhibit the
angiogenesis in RA. To demonstrate whether GEN inhibits the expression
of VEGF via the downstream pathways of IL-6, we further evaluated the
effect of GEN on the expression of VEGF in MH7A under the stimulation
of IL-6. As shown in Fig. 5, after stimulated with IL-6 (50 ng/mL), VEGF
mRNA was signiﬁcantly increased in MH7A cells and the protein level of
VEGF in the conditioned media was consistent with this trend. As ex-
pected, the expression and secretion of VEGF in MH7A was dose-
dependently decreased when pretreated with GEN. To understand the
relationship between GEN and JAK/STAT signalling pathway, which has
been proved to be the downstream pathway of IL-6, we tested the effect
of JAK/STAT signalling pathway inhibitors, AG490, on the expression of
VEGF. Delightfully, AG490 showed an effective inhibition on the
expression of VEGF induced by IL-6 in MH7A. In addition, GEN can also
inhibit the mRNA expression of JAK2 and STAT3 in MH7A cells. All of
these results indicate that GEN may inhibit the expression of VEGF and
angiogenesis via JAK/STAT signalling pathway in RA. It has been pointed
out that STAT3 is of great signiﬁcance in the pathogenesis of RA and is
expected to be a potential target for the treatment of RA [32,33].
Generally, STAT3 resides in the cytoplasm and can be activated by
various cytokines, such as IL-6 [34]. Once activated, the phosphorylated
STAT3 will match with another STAT protein to form homodimers or
heterodimers; thereafter, they translocate into the nucleus, bind to the
speciﬁc DNA elements, and initiate the process of gene expression [35]. It
has been identiﬁed that STAT3 can bind with the VEGF promoter and
thus exert direct inﬂuence on the expression of VEGF [36]. In this study,
our data also showed that GEN inhibited the expression of STAT3 and
VEGF simultaneously in MH7A cells. When treated with GEN, both the
activation and the nuclear translocation of activated STAT3 were
inhibited. These ﬁndings suggested that GEN can reduce the expression
of VEGF in MH7A under the stimulation of inﬂammatory factor, which is
realised by suppressing the activation and nuclear translocation of
STAT3, but the relevance of IL-6 and p-STAT3 was not clear. Many signal
Figure 5. GEN inhibits IL-6–induced VEGF
expression via JAK/STAT signalling pathway. (A)
Protein level of VEGF in the MH7A cell culture
supernatant; (B) mRNA expression of VEGF in
MH7A cells; (C) mRNA expression of JAK2 in
MH7A cells; (D) mRNA expression of STAT3 in
MH7A cells; (E) Western blotting of STAT3 and p-
STAT3; (F) immunoﬂuorescence image of p-STAT3
in the nuclear of MH7A (40 ); (G) immunoﬂuo-
rescence image of p-STAT3 in the nuclear of MH7A
(63 ) (*P < 0.05, **P < 0.01). GEN ¼ genistein;
IL-6 ¼ interleukin-6; VEGF ¼ vascular endothelial
growth factor; DAPi=4',6-diamidino-2-phenyl-
indole; GAPDH=Glyceraldehyde 3-phosphate
dehydrogenase.
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in our research, the JAK2/STAT3/VEGF signalling pathway was focused
and the result indicated that this signal pathway play an important role in
the treatment of RA using GEN. In conclusion, our data indicated that
GEN can inhibit the angiogenesis under an inﬂammation environment
and can suppress the inﬂammation-induced expression of VEGF in MH7A
cell partially through the IL-6/JAK2/STAT3/VEGF pathway, which
provide a new prospect for the treatment of RA.
Conclusion
In summary, the present results indicated that GEN might inhibit
angiogenesis, in which GEN suppressed angiogenesis partially through
JAK2/STAT3/VEGF signalling pathway, which has provided a novel
insight into the antiangiogenic activity of GEN in RA, for which GENmay
be a suitable candidate to develop a novel drug for RA treatment.
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